In contrast, biologics, such as IL-1 inhibitors, are frequently efficacious for patients with SAIDs.[44] Interestingly, there was a case report of refractory DM patient who responded well to anakinra, an IL-1 inhibitor.[45] In a clinical trial of anakinra in 15 inflammatory myositis patients, 3/4 DM patients showed symptomatic improvement. Here, IL1B is linked to dermatomyositis.